In this episode of Making Medicine, host John Stanford unpacks the Senate HELP Committee hearing on “The Future of Biotech.” From China’s accelerating investment to U.S. policy uncertainty, he explores what’s needed to protect American leadership in life sciences. The episode also covers new White House biosimilar announcements, gene therapy market challenges, and early insights from Incubate Policy Lab’s investment analysis. With over $14 billion invested in early-stage biotech this year, the conversation turns to what’s next for U.S. innovation.Do you think U.S. biotech can stay ahead of China? What policies would best support innovation? Should biosimilars have faster, simpler approvals?If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps:0:00 – Intro and disclaimer0:23 – Senate hearing: “The Future of Biotech” overview1:19 – China’s biotech rise and U.S. competitiveness concerns2:10 – IP protection, FDA modernization, and investment flight3:30 – NIH funding stability and bipartisan support4:00 – PBM reform and patient access challenges6:00 – John Crowley’s warning: U.S. could lose biotech leadership in 2–3 years8:00 – Incubate Policy Lab report: “Red lights in the U.S., green lights in China”10:00 – Policy solutions: pricing predictability and IP certainty12:00 – White House biosimilars announcement explained14:00 – Gene and cell therapy market struggles15:30 – AI-driven biotech investments and top-performing states17:00 – Incubate at JPM 2026 + FDA during government shutdown18:12 – Closing thoughts and audience shout-outsDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

Ver todos los episodios